advertisement
11.4 Prostaglandins (31)
Showing records 1 to 25
Display all abstracts in classification 11.4 Prostaglandins
Search within classification 11.4 Prostaglandins12518 Acute effects of PGF2α on MMP-2 secretion from human ciliary muscle cells: a PKC- and ERK-dependent process
Husain S; Jafri F; Crosson CE
Investigative Ophthalmology and Visual Science 2005; 46: 1706-1713
12438 Additivity of pilocarpine to bimatoprost in ocular hypertension and early glaucoma
Toor A; Chanis RA; Polikoff LA; Fahim MM; Sinha AP; Serle JB
Journal of Glaucoma 2005; 14: 243-248
12384 The safety and efficacy of travoprost 0.004%/timolol 0.5% fixed combination ophthalmic solution
Barnebey HS; Orengo-Nania S; Flowers BE; Samples J; Mallick S; Landry TA; Bergamini MV
American Journal of Ophthalmology 2005; 140: 1-7
12362 Safety and efficacy of bimatoprost 0.03% versus timolol maleate 0.5%/dorzolamide 2% fixed combination
Day DG; Sharpe ED; Beischel CJ; Jenkins JN; Stewart JA; Stewart WC
European Journal of Ophthalmology 2005; 15: 336-342
12181 Efficacy of the dorzolamide/timolol fixed combination versus latanoprost in the treatment of ocular hypertension or glaucoma: combined analysis of pooled data from two large randomized observer and patient-masked studies
Fechtner RD; McCarroll KA; Lines CR; Adamsons IA
Journal of Ocular Pharmacology and Therapeutics 2005; 21: 242-249
12425 Twenty-four-hour control with latanoprost-timolol-fixed combination therapy vs latanoprost therapy
Konstas AG; Boboridis K; Tzetzi D; Kallinderis K; Jenkins JN; Stewart WC
Archives of Ophthalmology 2005; 123: 898-902
12251 Potent reduction of intraocular pressure by nipradilol plus latanoprost in ocular hypertensive rabbits
Orihasi M; Shima Y; Tsuneki H; Kimura I
Biological & Pharmaceutical Bulletin 2005; 28: 65-68
12260 Latanoprost vs combined therapy with timolol plus dorzolamide in open-angle glaucoma: A 24-month study
Polo V; Larrosa JM; Ferreras A; Honrubia FM
Annals of ophthalmology (Skokie, Ill.) 2005; 37: 33-36
12293 The efficacy and safety of topical brinzolamide and dorzolamide when added to the combination therapy of latanoprost and a β-blocker in patients with glaucoma
Tsukamoto H; Noma H; Matsuyama S; Ikeda H; Mishima HK
Journal of Ocular Pharmacology and Therapeutics 2005; 21: 170-173
12155 The effects of bimatoprost and unoprostone isopropyl on the intraocular pressure of normal cats
Bartoe JT; Davidson HJ; Horton MT; Jung Y; Brightman AH
Veterinary Ophthalmology 2005; 8: 247-252
12440 Clinical predictors of latanoprost treatment effect
Bayer A; Henderer JD; Kwak T; Myers J; Fontanarosa J; Spaeth GL
Journal of Glaucoma 2005; 14: 260-263
12374 Lash ptosis caused by latanoprost
Casson RJ; Selva D
American Journal of Ophthalmology 2005; 139: 932-933
12335 Effects of latanoprost eye drops on the proliferation of human Tenon's fibroblasts in tissue culture
Chen YH; Sun XH
Chinese Journal of Ophthalmology 2005; 41: 620-624
12453 Incidence and severity of iris pigmentation on latanoprost-treated glaucoma eyes
Chou SY; Chou CK; Kuang TM; Hsu WM
Eye 2005; 19: 784-787
11738 Effects of the combination of bimatoprost and latanoprost on intraocular pressure in primary open angle glaucoma: a randomised clinical trial
Doi LM; Melo LA Jr; Prata JA Jr
British Journal of Ophthalmology 2005; 89: 547-549
12535 In vitro study of inflammatory potential and toxicity profile of latanoprost, travoprost, and bimatoprost in conjunctiva-derived epithelial cells
Guenoun JM; Baudouin C; Rat P; Pauly A; Warnet JM; Brignole-Baudouin F
Investigative Ophthalmology and Visual Science 2005; 46: 2444-2450
12190 Bunazosin, a selective α1-adrenoceptor antagonist, as an anti-glaucoma drug: Effects on ocular circulation and retinal neuronal damage
Hara H; Ichikawa M; Oku H; Shimazawa M; Araie M
Cardiovascular Drug Reviews 2005; 23: 43-56
12199 Incidence and profile of latanoprost nonresponders
Inoue K; Izumi M; Wakakura M; Inouye J; Tomita G
Japanese Journal of Clinical Ophthalmology 2005; 59: 553-557
12479 Effect of topical unoprostone isopropyl on optic nerve head circulation in controls and in normal-tension glaucoma patients
Kimura I; Shinoda K; Tanino T; Ohtake Y; Mashima Y
Japanese Journal of Ophthalmology 2005; 49: 287-293
12233 Hyperpigmentosis and hypertrichosis of the eyelids after use of bimatoprost eye drops
Modschiedler K; Von Den Driesch P; Paus R
Journal of the German Society of Dermatology 2005; 3: 276-277
12248 Changes of physiological intraocular pressure (IOP) in rabbits after amino acid lysine with antiglaucomatic drug latanoprost (Xalatan)
Olah Z; Veselovsky J; Gressnerova S; Vesela A
Česka a Slovenska Oftalmologie 2005; 61: 147-153
12538 Prostaglandin analogues and mouse intraocular pressure: effects of tafluprost, latanoprost, travoprost, and unoprostone, considering 24-hour variation
Ota T; Murata H; Sugimoto E; Aihara M; Araie M
Investigative Ophthalmology and Visual Science 2005; 46: 2006-2011
12262 The efficacy of bimatoprost 0.03% monotherapy in patients previously using topical β-blocker monotherapy for the treatment of glaucoma or ocular hypertension
Quinones R; Earl ML
Advances in Therapy 2004; 21: 370-379
12388 Efficacy and safety of a fixed combination of travoprost 0.004%/timolol 0.5% ophthalmic solution once daily for open-angle glaucoma or ocular hypertension
Schuman JS; Katz GJ; Lewis RA; Henry JC; Mallick S; Wells DT; Sullivan EK; Landry TA; Bergamini MV; Robertson SM
American Journal of Ophthalmology 2005; 140: 242
12279 Ocular hypotensive DP-class prostaglandin receptor affinities determined by quantitative autoradiography on human eye sections
Sharif NA; Davis TL; Williams GW
Journal of Ocular Pharmacology and Therapeutics 2005; 21: 121-132